University of Palermo

About: University of Palermo is a education organization based out in Palermo, Italy. It is known for research contribution in the topics: Population & Cancer. The organization has 15621 authors who have published 40250 publications receiving 964384 citations. The organization is also known as: Università degli Studi di Palermo & Universita degli Studi di Palermo.

Swings between rotation and accretion power in a binary millisecond pulsar

Abstract: We present the discovery of IGR J18245-2452, the first millisecond pulsar ob- served to swing between a rotation-powered, radio pulsar state, and an accretion-powered X-ray pulsar state (31). This transitional source represents the most convincing proof of the evolutionary link shared by accreting neutron stars in low mass X-ray binaries, and ra- dio millisecond pulsars. It demonstrates that swings between these two states take place on the same time-scales of luminosity variations of X-ray transients, and are therefore most easily interpreted in terms of changes in the rate of mass in-flow. While accreting mass, the X-ray emission of IGR J18245-2452 varies dramatically on time-scales ranging from a second to a few hours. We interpret a state characterised by a lower flux and pulsed fraction, and by sudden increases of the hardness of the X-ray emission, in terms of the onset of a magnetospheric centrifugal inhibition of the accretion flow. Prospects of finding new members of the newly established class of transitional pulsars are also briefly discussed.

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer

Abstract: The increasing evidence that gammadelta T cells have potent antitumor activity suggests their value in immunotherapy, particularly in areas of unmet need such as metastatic carcinoma. To this end, we initiated a phase I clinical trial in metastatic hormone-refractory prostate cancer to examine the feasibility and consequences of using the gammadelta T-cell agonist zoledronate, either alone or in combination with low-dose interleukin 2 (IL-2), to activate peripheral blood gammadelta cells. Nine patients were enlisted to each arm. Neither treatment showed appreciable toxicity. Most patients were treated with zoledronate + IL-2, but conversely only two treated with zoledronate displayed a significant long-term shift of peripheral gammadelta cells toward an activated effector-memory-like state (T(EM)), producing IFN-gamma and perforin. These patients also maintained serum levels of tumor necrosis factor-related apoptosis inducing ligand (TRAIL), consistent with a parallel microarray analysis showing that TRAIL is produced by gammadelta cells activated via the T-cell receptor and IL-2. Moreover, the numbers of T(EM) gammadelta cells showed a statistically significant correlation with declining prostate-specific antigen levels and objective clinical outcomes that comprised three instances of partial remission and five of stable disease. By contrast, most patients treated only with zoledronate failed to sustain either gammadelta cell numbers or serum TRAIL, and showed progressive clinical deterioration. Thus, zoledronate + IL-2 represents a novel, safe, and feasible approach to induce immunologic and clinical responses in patients with metastatic carcinomas, potentially providing a substantially increased window for specific approaches to be administered. Moreover, gammadelta cell phenotypes and possibly serum TRAIL may constitute novel biomarkers of prognosis upon therapy with zoledronate + IL-2 in metastatic carcinoma.